標(biāo)題: Titlebook: Medical Therapy of Ulcerative Colitis; Gary R. Lichtenstein Book 2014 Springer Science+Business Media New York 2014 Antiimetabolite therap [打印本頁] 作者: malcontented 時(shí)間: 2025-3-21 16:21
書目名稱Medical Therapy of Ulcerative Colitis影響因子(影響力)
書目名稱Medical Therapy of Ulcerative Colitis影響因子(影響力)學(xué)科排名
書目名稱Medical Therapy of Ulcerative Colitis網(wǎng)絡(luò)公開度
書目名稱Medical Therapy of Ulcerative Colitis網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Medical Therapy of Ulcerative Colitis被引頻次
書目名稱Medical Therapy of Ulcerative Colitis被引頻次學(xué)科排名
書目名稱Medical Therapy of Ulcerative Colitis年度引用
書目名稱Medical Therapy of Ulcerative Colitis年度引用學(xué)科排名
書目名稱Medical Therapy of Ulcerative Colitis讀者反饋
書目名稱Medical Therapy of Ulcerative Colitis讀者反饋學(xué)科排名
作者: 空氣傳播 時(shí)間: 2025-3-21 21:24
Prashant R. Mudireddy M.D.,Wojciech Blonski M.D., Ph.D.,Gary R. Lichtenstein M.D., F.A.C.P., F.A.C.Gnborn errors of purine metabolism (deficiency of hypoxanthine-guanine-phosphoribosyltransferase (HGPRT) and superactivity of phosphoribosylpyrophosphate (PRPP) synthetase), and as a secondary manifestation in several myeloproliferative and other hematological disorders. In addition to the above, pur作者: 民間傳說 時(shí)間: 2025-3-22 01:27 作者: bibliophile 時(shí)間: 2025-3-22 04:59 作者: panorama 時(shí)間: 2025-3-22 09:20
Hongha T. Vu M.D.,Themistocles Dassopoulos M.D.rtance.Reviews the importance of laboratory diagnosis, antif.Mycological studies of yeasts are entering a new phase, with the sequencing of multiple fungal genomes informing our understanding of their ability to cause disease and interact with the host. At the same time, the ongoing use of tradition作者: 無動(dòng)于衷 時(shí)間: 2025-3-22 16:42
Anthony M. Sofia M.D.,Sarah R. Goeppinger B.A.,David T. Rubin M.D.rtance.Reviews the importance of laboratory diagnosis, antif.Mycological studies of yeasts are entering a new phase, with the sequencing of multiple fungal genomes informing our understanding of their ability to cause disease and interact with the host. At the same time, the ongoing use of tradition作者: Living-Will 時(shí)間: 2025-3-22 19:24 作者: Tonometry 時(shí)間: 2025-3-22 22:26 作者: 類型 時(shí)間: 2025-3-23 05:04
Sushila Dalal M.D.,Russell D. Cohen M.D.rtance.Reviews the importance of laboratory diagnosis, antif.Mycological studies of yeasts are entering a new phase, with the sequencing of multiple fungal genomes informing our understanding of their ability to cause disease and interact with the host. At the same time, the ongoing use of tradition作者: Fracture 時(shí)間: 2025-3-23 08:34
Anita Afzali M.D., M.P.H.,Chelle L. Wheat M.P.H.,Scott D. Lee M.D.rtance.Reviews the importance of laboratory diagnosis, antif.Mycological studies of yeasts are entering a new phase, with the sequencing of multiple fungal genomes informing our understanding of their ability to cause disease and interact with the host. At the same time, the ongoing use of tradition作者: overshadow 時(shí)間: 2025-3-23 13:13
Seymour Katz M.D.rtance.Reviews the importance of laboratory diagnosis, antif.Mycological studies of yeasts are entering a new phase, with the sequencing of multiple fungal genomes informing our understanding of their ability to cause disease and interact with the host. At the same time, the ongoing use of tradition作者: 歡樂中國 時(shí)間: 2025-3-23 14:38 作者: Endearing 時(shí)間: 2025-3-23 21:46 作者: 破譯密碼 時(shí)間: 2025-3-23 23:07
Gregory P. Botta M.D., Ph.D.,Wojciech Blonski M.D., Ph.D.,Gary R. Lichtenstein M.D., F.A.C.P., F.A.Crtance.Reviews the importance of laboratory diagnosis, antif.Mycological studies of yeasts are entering a new phase, with the sequencing of multiple fungal genomes informing our understanding of their ability to cause disease and interact with the host. At the same time, the ongoing use of tradition作者: Moderate 時(shí)間: 2025-3-24 05:50
Andreas Fischer M.D.,Daniel C. Baumgart M.D., Ph.D.rtance.Reviews the importance of laboratory diagnosis, antif.Mycological studies of yeasts are entering a new phase, with the sequencing of multiple fungal genomes informing our understanding of their ability to cause disease and interact with the host. At the same time, the ongoing use of tradition作者: conscribe 時(shí)間: 2025-3-24 10:02 作者: 半導(dǎo)體 時(shí)間: 2025-3-24 13:09 作者: Intellectual 時(shí)間: 2025-3-24 16:01
The History of Medical Therapy of Ulcerative Colitis,derstanding of ulcerative colitis in the last 100 years. But there are several examples in the medical literature to suggest that a diarrheal disease similar to ulcerative colitis had been described many centuries ago.作者: 小平面 時(shí)間: 2025-3-24 20:06
The Role of the Food and Drug Administration in Medical Therapy for Ulcerative Colitis,tly incidence and prevalence rates have been rising in the rest of the world, particularly in Asia. The majority of UC patients are prescribed with medication for induction or maintenance of remission. In addition to standard therapies, recent developments in immunology have identified novel therape作者: 項(xiàng)目 時(shí)間: 2025-3-24 23:12 作者: lambaste 時(shí)間: 2025-3-25 07:18 作者: integrated 時(shí)間: 2025-3-25 09:52
The Importance of Mucosal Healing in Ulcerative Colitis,tory damage, confined exclusively to the mucosa of the colorectum, is the hallmark of the disease. The inflammation is characteristically superficial in nature and appears to begin in the rectum with variable extension to more proximal portions of the colon. This inflammation, and subsequent loss of作者: 思想 時(shí)間: 2025-3-25 14:37 作者: Intentional 時(shí)間: 2025-3-25 15:55 作者: 愉快嗎 時(shí)間: 2025-3-25 22:37
Topical Mesalamine,he distal 60 cm of the colon, can be effectively treated with both oral and topical mesalamine formulations. The current 2010 American College of Gastroenterology guidelines state that for mild to moderate distal ulcerative colitis, topical mesalamine is superior to oral mesalamine or topical steroi作者: Conclave 時(shí)間: 2025-3-26 03:54 作者: Derogate 時(shí)間: 2025-3-26 08:06
Rectal Glucocorticoid Use in Ulcerative Colitis,mas have been used for over 50 years, yet experience favors topical 5-ASA as the more effective therapy. Safety issues include additional risk factors with prolonged topical corticosteroid use. Newer formulations using a first-pass metabolism feature (budesonide or beclomethasone dipropionate (BDP))作者: headway 時(shí)間: 2025-3-26 08:36 作者: ACE-inhibitor 時(shí)間: 2025-3-26 15:20
,Azathioprine/6-Mercaptopurine Metabolism in Ulcerative Colitis: A Guide to Metabolite Assessment—Anmerica; about half have unremitting disease with symptoms of abdominal pain and diarrhea that impact patient’s quality of life and work-related productivity. It stands to reason that the major goal of therapy for physicians caring for patients with inflammatory bowel disease is to achieve and sustai作者: Control-Group 時(shí)間: 2025-3-26 17:50
Cyclosporine for Ulcerative Colitis,d epithelium extends continuously from the rectum and involves part or all (pancolitis) of the colon. Symptomatically, patients exhibit increased, bloody, bowel movements with fecal urgency, diarrhea, abdominal cramping, abdominal pain, hematochezia, and fever. These characteristics can have a gradu作者: 考古學(xué) 時(shí)間: 2025-3-26 21:20
Tacrolimus, Sirolimus, and Mycophenolate Mofetil,osporine, especially in the long run, appears rather unfavorable. Neurological side effects such as paresthesias, nephrotoxicity, hypertension, headache, and gingival hyperplasia have been reported in up to one third of patients. As a consequence, an intense search for novel calcineurin inhibitors c作者: keloid 時(shí)間: 2025-3-27 03:35 作者: 剛開始 時(shí)間: 2025-3-27 06:22
Beyond Infliximab: Other Anti-TNF Therapies for Ulcerative Colitis,a chimeric monoclonal antibody to tumor necrosis factor-alpha (TNF-α), for Crohn’s disease (CD). However, it was not until 2005, after the results of several open-label clinical studies and of the ACT1 and ACT2 trials of IFX for treatment of moderate to severe ulcerative colitis (UC), that this agen作者: 蘑菇 時(shí)間: 2025-3-27 10:02 作者: dearth 時(shí)間: 2025-3-27 14:53 作者: ALOFT 時(shí)間: 2025-3-27 21:22 作者: itinerary 時(shí)間: 2025-3-27 22:11
ation we report that several glycogenolytic hormones exert a stimulatory effect on the rate of PRPP and purine synthesis in mouse liver in vivo (4, 5). Our studies concerning the mechanism of this phenomenon are discribed.作者: 紳士 時(shí)間: 2025-3-28 02:26
Prashant R. Mudireddy M.D.,Wojciech Blonski M.D., Ph.D.,Gary R. Lichtenstein M.D., F.A.C.P., F.A.C.Gation we report that several glycogenolytic hormones exert a stimulatory effect on the rate of PRPP and purine synthesis in mouse liver in vivo (4, 5). Our studies concerning the mechanism of this phenomenon are discribed.作者: molest 時(shí)間: 2025-3-28 08:18
Farzana Rashid M.D.,Gary R. Lichtenstein M.D., F.A.C.P., F.A.C.G., A.G.A.F.作者: Astigmatism 時(shí)間: 2025-3-28 13:25 作者: sleep-spindles 時(shí)間: 2025-3-28 15:06
Pascal Juillerat M.D., M.Sc.,Joshua R. Korzenik M.D.作者: 吃掉 時(shí)間: 2025-3-28 21:56
Conor Lahiff M.D.,Alan C. Moss M.D.,Adam S. Cheifetz M.D.veral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: 全部逛商店 時(shí)間: 2025-3-29 00:07
Sunil Samuel M.B.B.S., Ph.D.,Edward V. Loftus Jr. M.D.veral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: 善辯 時(shí)間: 2025-3-29 04:39
Hongha T. Vu M.D.,Themistocles Dassopoulos M.D.veral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: ATRIA 時(shí)間: 2025-3-29 09:57
Anthony M. Sofia M.D.,Sarah R. Goeppinger B.A.,David T. Rubin M.D.veral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: 大廳 時(shí)間: 2025-3-29 14:32
Atsushi Sakuraba M.D., Ph.D.veral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: medieval 時(shí)間: 2025-3-29 16:07
Prashant R. Mudireddy M.D.,Wojciech Blonski M.D., Ph.D.,Gary R. Lichtenstein M.D., F.A.C.P., F.A.C.Gveral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: ARENA 時(shí)間: 2025-3-29 22:52 作者: CUR 時(shí)間: 2025-3-30 02:25
Anita Afzali M.D., M.P.H.,Chelle L. Wheat M.P.H.,Scott D. Lee M.D.veral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: forecast 時(shí)間: 2025-3-30 06:00
Seymour Katz M.D.veral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: obnoxious 時(shí)間: 2025-3-30 08:11
María Chaparro M.D., Ph.D.,Javier P. Gisbert M.D., Ph.D.veral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: 用手捏 時(shí)間: 2025-3-30 15:11
Carmen Cuffari M.D.veral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: Ringworm 時(shí)間: 2025-3-30 17:55 作者: disciplined 時(shí)間: 2025-3-30 22:30
Andreas Fischer M.D.,Daniel C. Baumgart M.D., Ph.D.veral pathogenic yeasts, including Candida, Cryptococcus, Malassezia and yeasts of emerging importance. The importance of laboratory diagnosis, antifungal susceptibility testing, antifungal resistance and yeast diseases in animals are reviewed..978-3-642-26141-1978-3-642-03150-2Series ISSN 2626-885X Series E-ISSN 2626-8868 作者: Ankylo- 時(shí)間: 2025-3-31 03:22 作者: 問到了燒瓶 時(shí)間: 2025-3-31 05:34 作者: 投射 時(shí)間: 2025-3-31 12:49
Principles of Medical Management of Ulcerative Colitis, of UC patients, with a focus on evidence-based, patient-centered, systematic, and comprehensive therapy. We provide an overview of the therapeutic options and goals of treatment and provide recommendations for individualizing treatment.作者: dissolution 時(shí)間: 2025-3-31 13:51 作者: 不足的東西 時(shí)間: 2025-3-31 18:39
Antimetabolite Therapy in Ulcerative Colitis: Azathioprine, 6-Mercaptopurine, and Methotrexate,ng the use of thiopurines—azathioprine and mercaptopurine—and methotrexate are more robust in steroid-dependent Crohn’s disease than in UC. This chapter will review the current state of the art regarding the thiopurine drugs and methotrexate for the treatment of UC.作者: 現(xiàn)代 時(shí)間: 2025-4-1 01:39
